NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri(Dana-Farber Cancer Institute), Jeffrey D. Wayne(Northwestern University), Ronald P. DeMatteo(University of Pennsylvania), Kristen N. Ganjoo(Stanford Medicine), Chandrajit P. Raut(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Richard F. Riedel(Heidelberg University), Hema Sundar(National Comprehensive Cancer Network), Margaret von Mehren(Temple University Health System), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Jonathan C. Trent(University of Miami), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Scott M. Schuetze(University of Michigan)
Cited by 1,222
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k